Memantine Treatment in Fragile X-Associated Tremor/Ataxia Syndrome

University of California (UC) Davis

Status: Completed

Conditions: Fragile X-Associated Tremor/Ataxia Syndrome; Fragile X Premutation Carriers

Treatments: Drug: Memantine; Drug: Placebo

Study type: Interventional

Funder types: Other; Industry; NIH

Identifiers

NCT00584948

200715426-1

1RL1AG032115-01 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

The purpose of this study is to determine if memantine is effective in treating symptoms of Fragile X-associated Tremor Ataxia Syndrome.

Enrollment: 94 patients

Sex: All

Ages: 30 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Fragile X premutation carrier (CGG repeat 55-200)with neurological symptoms; Clinical FXTAS Stage 1-5

Exclusion criteria

• Previous reaction to memantine

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

94 participants in 2 patient groups, including a placebo group

Memantine

Experimental group

Treatment:

Drug: Memantine

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo